SLC12A1 (Q13621) variants and mutations
SLC12A1 (also known as Q13621) is a human protein-coding gene encoding a solute carrier family 12 member 1 protein. It reabsorbs sodium, potassium, and chloride in the thick ascending limb of the kidney, helping generate the medullary concentration gradient and maintain salt balance. Biallelic loss-of-function variants cause Bartter syndrome type 1 with renal salt wasting. This analysis covers 1,860 SLC12A1 variants and mutations. Of these, 71% have computational variant effect predictions. Disease context includes Bartter disease type 1, Bartter syndrome, and nephrotic syndrome. Example SLC12A1 variants include S2L, S2*, and S2S.
Variant analysis overview
- Gene: SLC12A1
- Protein: Q13621
- UniProt accession: Q13621
- Organism: Homo sapiens
- Variants analyzed: 1860
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,585 unspecified-consequence records; 142 missense variants; 5 stop-gained variants; 99 synonymous variants; 24 frameshift variants; 2 in-frame deletions; 3 substitution
- Prediction scores: 1,312 variants have prediction scores (71% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Bartter disease type 1, Bartter syndrome, nephrotic syndrome, hypertensive disorder, congestive heart failure, kidney disorder, cirrhosis of liver, heart failure, cardiovascular disorder, Hypertension, pulmonary edema, chronic kidney disease.
Protein structure and variant hotspots
- Protein features: 10 transmembrane segments; 11 post-translational modification sites.
- Structural context: 297 variants have structural context.
- PTM context: 40 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable SLC12A1 variants
Examples include S2L, S2*, S2S, L3L, L3M, N4N, N5D, N5S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- S2L (p.Ser2Leu), gnomAD 15-48207724-C-T, REVEL 0.49, MetaLR 0.73
- S2* (p.Ser2Ter), gnomAD 15-48207724-C-A, CADD 35.00
- S2S (p.Ser2Ser), gnomAD 15-48207725-A-G, CADD 6.21
- L3L (p.Leu3Leu), rs752937144, gnomAD 15-48207726-C-T, CADD 5.72
- L3M (p.Leu3Met), gnomAD 15-48207726-C-A, REVEL 0.26, MetaLR 0.38
- N4N (p.Asn4Asn), gnomAD 15-48207731-C-T, CADD 7.59
- N5D (p.Asn5Asp), rs387907466, ClinGen CA216072, ClinVar RCV000054592, Ensembl rs387907466, AlphaMissense 0.13, MetaLR 0.51, Uncertain significance, not provided
- N5S (p.Asn5Ser), rs376723001, ClinGen CA7546677, cosmic curated COSV10037, ClinVar RCV002589667, REVEL 0.25, MetaLR 0.44, Uncertain significance, not provided
- N5N (p.Asn5Asn), gnomAD 15-48207734-C-T, CADD 7.61
- N5K (p.Asn5Lys), gnomAD 15-48207734-C-A, REVEL 0.21, MetaLR 0.44
- S6P (p.Ser6Pro), gnomAD rs1232353451, REVEL 0.23, MetaLR 0.40
- S6S (p.Ser6Ser), rs1485986083, gnomAD 15-48207737-T-C, CADD 11.80
- S7Y (p.Ser7Tyr), TOPMed rs1051687018, gnomAD rs1051687018, REVEL 0.39, MetaLR 0.57
- S7S (p.Ser7Ser), gnomAD 15-48207740-C-G, CADD 9.76
- N8D (p.Asn8Asp), Ensembl rs2040998684, REVEL 0.22, MetaLR 0.45
- N8S (p.Asn8Ser), gnomAD rs1238693222, REVEL 0.20, MetaLR 0.37, Uncertain significance, Bartter disease type 1
- N8K (p.Asn8Lys), gnomAD 15-48207743-T-A, REVEL 0.22, MetaLR 0.43
- N8N (p.Asn8Asn), gnomAD 15-48207743-T-C, CADD 2.68
- V9A (p.Val9Ala), rs764642727, ClinGen CA7546678, ClinVar RCV001365018, ExAC rs764642727, REVEL 0.16, MetaLR 0.48, Uncertain significance, not provided
- V9I (p.Val9Ile), TOPMed rs1352768200, gnomAD rs1352768200, REVEL 0.19, MetaLR 0.47
- F10L (p.Phe10Leu), 1000Genomes rs527699495, REVEL 0.45, MetaLR 0.66
- F10S (p.Phe10Ser), gnomAD rs1286870736, REVEL 0.50, MetaLR 0.65
- L11M (p.Leu11Met), cosmic curated COSV10814
- L11L (p.Leu11Leu), gnomAD 15-48207750-C-T, CADD 8.95
- S13L (p.Ser13Leu), cosmic curated COSV10521
- V14A (p.Val14Ala), ExAC rs754371455, gnomAD rs754371455, REVEL 0.24, MetaLR 0.43
- V14L (p.Val14Leu), gnomAD rs1487108450, REVEL 0.20, MetaLR 0.43
- P15L (p.Pro15Leu), gnomAD rs1191556534, REVEL 0.20, MetaLR 0.47
- P15S (p.Pro15Ser), rs1027458847, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, NCI-TCGA Cosmic COSV5770, REVEL 0.15, MetaLR 0.42, Variant assessed as somatic; moderate impact.
- P15T (p.Pro15Thr), cosmic curated COSV57709
- P15I (p.Pro15Ile), gnomAD 15-48207761-GCCCA, CADD 25.00
- S16C (p.Ser16Cys), Ensembl rs2040999005
- S16I (p.Ser16Ile), cosmic curated COSV57711
- S16G (p.Ser16Gly), gnomAD 15-48207765-A-G, REVEL 0.18, MetaLR 0.49
- S16T (p.Ser16Thr), gnomAD 15-48207766-G-C, REVEL 0.15, MetaLR 0.39
- N17S (p.Asn17Ser), rs757876818, ClinGen CA7546680, ClinVar RCV002698533, ClinVar RCV003900920, REVEL 0.12, MetaLR 0.36, Uncertain significance, Inborn genetic diseases; not provided; Bartter disease type 1
- N17N (p.Asn17Asn), gnomAD 15-48207770-T-C, CADD 7.71
- T18N (p.Thr18Asn), cosmic curated COSV57709
- T18T (p.Thr18Thr), gnomAD 15-48207773-C-T, CADD 6.85
- N19D (p.Asn19Asp), TOPMed rs2040999078, gnomAD rs2040999078, REVEL 0.23, MetaLR 0.42
- N19S (p.Asn19Ser), gnomAD rs1433968969, REVEL 0.21, MetaLR 0.34
- R20C (p.Arg20Cys), cosmic curated COSV10521, ExAC rs764832819, TOPMed rs764832819, gnomAD rs764832819, REVEL 0.61, MetaLR 0.76
- R20G (p.Arg20Gly), cosmic curated COSV10037, REVEL 0.58, MetaLR 0.76
- R20H (p.Arg20His), rs34661166, ClinGen CA7546682, cosmic curated COSV57712, ClinVar RCV001118372, REVEL 0.60, MetaLR 0.78, Conflicting interpretations, not provided; Bartter disease type 1
- R20S (p.Arg20Ser), gnomAD 15-48207777-C-A, REVEL 0.57, MetaLR 0.76
- R20L (p.Arg20Leu), gnomAD 15-48207778-G-T, REVEL 0.75, MetaLR 0.78
- F21L (p.Phe21Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F21S (p.Phe21Ser), TOPMed rs1455832531, gnomAD rs1455832531, REVEL 0.69, MetaLR 0.76
- F21Y (p.Phe21Tyr), TOPMed rs1455832531, gnomAD rs1455832531, REVEL 0.63, MetaLR 0.72
- Q22* (p.Gln22Ter), rs2140999192, ClinGen CA392331091, ClinVar RCV003716206, Ensembl rs2140999192, CADD 36.00, Pathogenic
- Q22H (p.Gln22His), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- V23I (p.Val23Ile), gnomAD rs1159731549, REVEL 0.46, MetaLR 0.74
- V23V (p.Val23Val), gnomAD 15-48207788-T-A, CADD 4.48
- S24I (p.Ser24Ile), cosmic curated COSV57710, REVEL 0.35, MetaLR 0.47
- S24N (p.Ser24Asn), rs35342218, ClinGen CA7546683, ClinVar RCV000959217, 1000Genomes rs35342218, REVEL 0.22, MetaLR 0.26, Benign/Likely benign, not provided
- S24T (p.Ser24Thr), gnomAD 15-48207790-G-C, REVEL 0.28, MetaLR 0.47
- S24S (p.Ser24Ser), rs1386489934, gnomAD 15-48207791-T-C, CADD 10.70
- V25A (p.Val25Ala), TOPMed rs1362910374, gnomAD rs1362910374, REVEL 0.35, MetaLR 0.52
- V25G (p.Val25Gly), cosmic curated COSV57711
- V25V (p.Val25Val), rs779764287, gnomAD 15-48207794-C-G, CADD 6.60
- I26V (p.Ile26Val), gnomAD 15-48207795-A-G, REVEL 0.20, MetaLR 0.37
- N27K (p.Asn27Lys), ExAC rs746746098, gnomAD rs746746098, REVEL 0.22, MetaLR 0.43
- N27N (p.Asn27Asn), rs746746098, gnomAD 15-48207800-T-C, CADD 3.15
- E28* (p.Glu28Ter), cosmic curated COSV10037
- E28D (p.Glu28Asp), cosmic curated COSV57709
- E28K (p.Glu28Lys), gnomAD 15-48207801-G-A, REVEL 0.59, MetaLR 0.17
- N29D (p.Asn29Asp), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- N29S (p.Asn29Ser), gnomAD 15-48207805-A-G, REVEL 0.14, MetaLR 0.05
- N29K (p.Asn29Lys), gnomAD 15-48207806-C-A, REVEL 0.11, MetaLR 0.05
- N29N (p.Asn29Asn), gnomAD 15-48207806-C-T, CADD 3.98
- H30D (p.His30Asp), rs199719506, ClinGen CA7546686, ClinVar RCV002766216, ClinVar RCV002775283, REVEL 0.24, MetaLR 0.42, Uncertain significance, Inborn genetic diseases; not provided
- H30H (p.His30His), rs143744003, gnomAD 15-48207809-T-C, CADD 0.43
- E31D (p.Glu31Asp), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- E31G (p.Glu31Gly), ExAC rs111352042, gnomAD rs111352042, REVEL 0.17, MetaLR 0.05
- E31K (p.Glu31Lys), ESP rs375884289, TOPMed rs375884289, gnomAD rs375884289, REVEL 0.19, MetaLR 0.06, Uncertain significance, Bartter disease type 1; Inborn genetic diseases
- E31E (p.Glu31Glu), rs1239472886, gnomAD 15-48207812-G-A, CADD 3.03
- S32G (p.Ser32Gly), Ensembl rs112849624
- S33C (p.Ser33Cys), gnomAD 15-48207816-A-T, REVEL 0.14, MetaLR 0.40
- S33T (p.Ser33Thr), gnomAD 15-48207817-G-C, REVEL 0.07, MetaLR 0.05
- S33S (p.Ser33Ser), rs769791561, gnomAD 15-48207818-T-C, CADD 1.14
- A34T (p.Ala34Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A34V (p.Ala34Val), cosmic curated COSV57711
- A34A (p.Ala34Ala), rs2040999699, gnomAD 15-48207821-A-T, CADD 0.09
- A35T (p.Ala35Thr), gnomAD 15-48207822-G-A, REVEL 0.16, MetaLR 0.41
- A36G (p.Ala36Gly), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- A36S (p.Ala36Ser), gnomAD 15-48207825-G-T, REVEL 0.22, MetaLR 0.47
- A36A (p.Ala36Ala), gnomAD 15-48207827-A-T, CADD 0.18
- D37E (p.Asp37Glu), NCI-TCGA Cosmic COSV5770, cosmic curated COSV57709, Variant assessed as somatic; moderate impact.
- D37G (p.Asp37Gly), rs774355538, ClinGen CA7546690, ClinVar RCV002028321, ExAC rs774355538, REVEL 0.14, MetaLR 0.03, Uncertain significance, not provided
- D37N (p.Asp37Asn), gnomAD 15-48207828-G-A, REVEL 0.18, MetaLR 0.45
- D38A (p.Asp38Ala), 1000Genomes rs150581202, ExAC rs150581202, gnomAD rs150581202, REVEL 0.15, MetaLR 0.04
- D38E (p.Asp38Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D38G (p.Asp38Gly), cosmic curated COSV10609
- D38Y (p.Asp38Tyr), gnomAD rs1214617731, REVEL 0.19, MetaLR 0.04
- D38N (p.Asp38Asn), gnomAD 15-48207831-G-A, REVEL 0.15, MetaLR 0.04
- D38D (p.Asp38Asp), rs2040999845, gnomAD 15-48207833-C-T, CADD 0.53
- N39H (p.Asn39His), TOPMed rs1488930297, gnomAD rs1488930297, REVEL 0.18, MetaLR 0.43
- N39K (p.Asn39Lys), TOPMed rs1209422628, gnomAD rs1209422628
- T40A (p.Thr40Ala), rs772144467, ClinGen CA7546692, ClinVar RCV001885667, ClinVar RCV002490090, REVEL 0.23, MetaLR 0.31, Uncertain significance, not provided; Bartter disease type 1
- T40N (p.Thr40Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T40S (p.Thr40Ser), gnomAD 15-48207838-C-G, REVEL 0.15, MetaLR 0.38
- D41G (p.Asp41Gly), NCI-TCGA Cosmic COSV5770, cosmic curated COSV57709, Variant assessed as somatic; moderate impact.
- D41H (p.Asp41His), gnomAD rs2037423993, REVEL 0.42, MetaLR 0.72
- D41N (p.Asp41Asn), cosmic curated COSV10642
- D41V (p.Asp41Val), Ensembl rs2040999950
- D41A (p.Asp41Ala), gnomAD 15-48207841-A-C, REVEL 0.43, MetaLR 0.11
- P42L (p.Pro42Leu), ExAC rs760852272, TOPMed rs760852272, gnomAD rs760852272, REVEL 0.49, MetaLR 0.55
- P42S (p.Pro42Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P42T (p.Pro42Thr), gnomAD 15-48207843-C-A, REVEL 0.37, MetaLR 0.47
- P42P (p.Pro42Pro), rs1380299890, gnomAD 15-48207845-A-T, CADD 2.75
- P43A (p.Pro43Ala), gnomAD rs979590503, REVEL 0.40, MetaLR 0.52, Uncertain significance, Bartter disease type 1
- P43L (p.Pro43Leu), ExAC rs764518121, TOPMed rs764518121, gnomAD rs764518121
- P43S (p.Pro43Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H44Y (p.His44Tyr), Ensembl rs2041000204, REVEL 0.38, MetaLR 0.46
- H44H (p.His44His), gnomAD 15-48207851-T-C, CADD 7.02
- Y45F (p.Tyr45Phe), gnomAD 15-48207853-A-T, REVEL 0.38, MetaLR 0.53
- Y45Y (p.Tyr45Tyr), rs1368474114, gnomAD 15-48207854-T-C, CADD 7.28
- E46K (p.Glu46Lys), 1000Genomes rs549854027, REVEL 0.52, MetaLR 0.11
- E46E (p.Glu46Glu), gnomAD 15-48207857-A-G, CADD 8.49
- T48A (p.Thr48Ala), Ensembl rs2140999342
- T48N (p.Thr48Asn), ExAC rs777199828, gnomAD rs777199828, REVEL 0.43, MetaLR 0.47, Uncertain significance, Inborn genetic diseases
- T48S (p.Thr48Ser), ExAC rs777199828, gnomAD rs777199828, REVEL 0.38, MetaLR 0.52
- T48I (p.Thr48Ile), gnomAD 15-48207862-C-T, REVEL 0.49, MetaLR 0.69
- S49F (p.Ser49Phe), cosmic curated COSV57709, REVEL 0.56, MetaLR 0.74
- S49Y (p.Ser49Tyr), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, NCI-TCGA Cosmic COSV5770, Variant assessed as somatic; moderate impact.
- S49L (p.Ser49Leu), gnomAD 15-48207861-AC-A, CADD 27.10
- F50I (p.Phe50Ile), gnomAD 15-48207867-T-A, REVEL 0.37, MetaLR 0.51
- F50F (p.Phe50Phe), gnomAD 15-48207869-T-C, CADD 9.35
- G51E (p.Gly51Glu), TOPMed rs1291382750, gnomAD rs1291382750, REVEL 0.29, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- G51R (p.Gly51Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G51W (p.Gly51Trp), gnomAD 15-48207870-G-T, REVEL 0.39, MetaLR 0.09
- D52Y (p.Asp52Tyr), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- D52N (p.Asp52Asn), gnomAD 15-48207873-G-A, REVEL 0.29, MetaLR 0.46
- E53* (p.Glu53Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E53A (p.Glu53Ala), gnomAD rs1398145405, REVEL 0.22, MetaLR 0.11
- Q55R (p.Gln55Arg), ESP rs368901120, TOPMed rs368901120, REVEL 0.17, MetaLR 0.09
- K56E (p.Lys56Glu), gnomAD 15-48207885-A-G, REVEL 0.24, MetaLR 0.43
- R57D (p.Arg57Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R57T (p.Arg57Thr), rs141683652, ClinGen CA7546698, ClinVar RCV002701793, ClinVar RCV005002983, REVEL 0.54, MetaLR 0.65, Conflicting interpretations, not provided; Bartter disease type 1; Inborn genetic diseases
- L58F (p.Leu58Phe), TOPMed rs959913904, gnomAD rs959913904, REVEL 0.15, MetaLR 0.37
- L58R (p.Leu58Arg), ExAC rs749839008, gnomAD rs749839008, REVEL 0.41, MetaLR 0.10
- L58P (p.Leu58Pro), gnomAD 15-48207892-T-C, REVEL 0.49, MetaLR 0.10
- L58L (p.Leu58Leu), gnomAD 15-48207893-C-T, CADD 7.17
- I60F (p.Ile60Phe), ExAC rs757961565, gnomAD rs757961565, REVEL 0.30, MetaLR 0.48
- S61G (p.Ser61Gly), cosmic curated COSV57710
- S61N (p.Ser61Asn), TOPMed rs1463785529, REVEL 0.40, MetaLR 0.53
- S61R (p.Ser61Arg), cosmic curated COSV57710
- S61T (p.Ser61Thr), gnomAD 15-48207901-G-C, REVEL 0.37, MetaLR 0.53
- F62L (p.Phe62Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R63* (p.Arg63Ter), rs2041000812, ClinGen CA2175404641, ClinVar RCV003671467, Pathogenic
- R63T (p.Arg63Thr), cosmic curated COSV57708, ExAC rs765902420, TOPMed rs765902420, gnomAD rs765902420, REVEL 0.48, MetaLR 0.57
- R63R (p.Arg63Arg), rs35240149, gnomAD 15-48207908-G-A, CADD 8.03
- P64T (p.Pro64Thr), ExAC rs754666663, TOPMed rs754666663, gnomAD rs754666663, REVEL 0.38, MetaLR 0.48, Uncertain significance, Inborn genetic diseases; Bartter disease type 1
- P64L (p.Pro64Leu), gnomAD 15-48207910-C-T, REVEL 0.36, MetaLR 0.50
- P64P (p.Pro64Pro), gnomAD 15-48207911-T-C, CADD 11.00
- G65R (p.Gly65Arg), gnomAD rs2041000957
- G65G (p.Gly65Gly), rs1263945901, gnomAD 15-48207914-G-A, CADD 8.32
- Q67K (p.Gln67Lys), cosmic curated COSV57709
- Q67R (p.Gln67Arg), rs139471047, ClinGen CA7546704, ClinVar RCV001806946, ClinVar RCV005006066, REVEL 0.17, MetaLR 0.05, Conflicting interpretations, not provided; Bartter disease type 1; Inborn genetic diseases
- Q67Q (p.Gln67Gln), rs373986868, gnomAD 15-48207920-G-A, CADD 8.18
- E68D (p.Glu68Asp), NCI-TCGA Cosmic COSV5770, cosmic curated COSV57708, Variant assessed as somatic; moderate impact.
- E68Q (p.Glu68Gln), gnomAD 15-48207921-G-C, REVEL 0.23, MetaLR 0.11
- E68E (p.Glu68Glu), gnomAD 15-48207923-G-A, CADD 8.32
- C69F (p.Cys69Phe), rs143141941, ClinGen CA7546707, ClinVar RCV000879871, 1000Genomes rs143141941, REVEL 0.21, MetaLR 0.45, Likely benign, not provided
- C69G (p.Cys69Gly), cosmic curated COSV10521
- C69R (p.Cys69Arg), ExAC rs201119328, TOPMed rs201119328, gnomAD rs201119328, REVEL 0.21, MetaLR 0.36, Uncertain significance, Bartter disease type 1
- C69S (p.Cys69Ser), NCI-TCGA Cosmic COSV5770, cosmic curated COSV57708, Variant assessed as somatic; moderate impact.
- C69Y (p.Cys69Tyr), rs143141941, ClinGen CA392331410, ClinVar RCV000713321, ClinVar RCV000765215, REVEL 0.23, MetaLR 0.45, Uncertain significance, Bartter disease type 1; not provided
- C69C (p.Cys69Cys), gnomAD 15-48207926-C-T, CADD 9.65
- Y70C (p.Tyr70Cys), rs1185924805, gnomAD rs1185924805, REVEL 0.53, MetaLR 0.59, Variant assessed as somatic; moderate impact.
- Y70Y (p.Tyr70Tyr), rs1413918873, gnomAD 15-48207929-T-C, CADD 7.00
- D71Y (p.Asp71Tyr), gnomAD 15-48207930-G-T, REVEL 0.50, MetaLR 0.11
- D71N (p.Asp71Asn), gnomAD 15-48207930-G-A, REVEL 0.20, MetaLR 0.11
- D71E (p.Asp71Glu), gnomAD 15-48207932-C-G, REVEL 0.18, MetaLR 0.08
- N72N (p.Asn72Asn), rs2041001270, gnomAD 15-48207935-T-C, CADD 8.51
- F73L (p.Phe73Leu), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, NCI-TCGA Cosmic COSV5770, Variant assessed as somatic; moderate impact.
- F73S (p.Phe73Ser), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10037, Variant assessed as somatic; moderate impact.
- L74F (p.Leu74Phe), gnomAD rs1422768026, REVEL 0.26, MetaLR 0.60
- L74H (p.Leu74His), gnomAD 15-48207940-T-A, REVEL 0.38, MetaLR 0.09
- L74L (p.Leu74Leu), rs1162084251, gnomAD 15-48207941-C-G, CADD 6.82
Public SLC12A1 analysis runs
- SLC12A1 analysis run — SLC12A1 (1,860 variants) — completed 2026-08-19